Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Current Leases (2019 - 2025)

Purple Biotech has reported Current Leases over the past 4 years, most recently at $194000.0 for Q4 2022.

  • Quarterly Current Leases fell 2.51% to $194000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $194000.0 through Dec 2022, down 2.51% year-over-year, with the annual reading at $194000.0 for FY2022, 2.51% down from the prior year.
  • Current Leases was $194000.0 for Q4 2022 at Purple Biotech, up from $193000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $207000.0 in Q4 2020 and troughed at $109000.0 in Q2 2020.
  • The 4-year median for Current Leases is $197000.0 (2019), against an average of $190833.3.
  • Year-over-year, Current Leases crashed 43.81% in 2020 and then skyrocketed 82.57% in 2021.
  • A 4-year view of Current Leases shows it stood at $195000.0 in 2019, then increased by 6.15% to $207000.0 in 2020, then decreased by 3.86% to $199000.0 in 2021, then dropped by 2.51% to $194000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Current Leases are $194000.0 (Q4 2022), $193000.0 (Q3 2022), and $195000.0 (Q2 2022).